{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:34:01Z","timestamp":1760524441238},"reference-count":165,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2022,12,2]]},"DOI":"10.1080\/13543784.2022.2160313","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T08:59:01Z","timestamp":1671526741000},"page":"1339-1357","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers"],"prefix":"10.1080","volume":"31","author":[{"given":"Raffaella","family":"Cioffi","sequence":"first","affiliation":[{"name":"Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Galli","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Rabaiotti","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Candiani","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Pella","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Candotti","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Bocciolone","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"De Marzi","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Mangili","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Bergamini","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.13878)"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00662"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz062"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.007"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01009"},{"issue":"2","key":"cit0007","first-page":"573","volume":"71","author":"Lynch HT","year":"1993","journal-title":"Cancer"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705153362001"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000180854.28831.77"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00194"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcsup.2020.02.003"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.08.024"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.07.112"},{"key":"cit0014","unstructured":"Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial icon-6."},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.6056"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.6003"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-002073"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.020"},{"key":"cit0019","unstructured":"Randomized Phase I\/II Study of AVB-S6-500 in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (2019-2022. NCT04019288."},{"key":"cit0020","unstructured":"Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: a prospective, single-arm, single-center, phase II clinical study. J Clin Oncol. https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2020.38.15_suppl.6061"},{"key":"cit0021","unstructured":"A prospective, single-arm, multicenter, exploratory phase ii study to evaluate the efficacy and safety of anlotinib combined with carboplatin\/paclitaxel as first-line treatment in patients with advanced ovarian cancer. (NCT04807166)."},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.06.032"},{"key":"cit0023","unstructured":"Phase II study with safety lead-in of lenvatinib, pembrolizumab, and weekly paclitaxel for recurrent endometrial, epithelial ovarian, fallopian tube and primary peritoneal cancer. NCT04781088."},{"key":"cit0024","unstructured":"Immunomodulation of the tumor microenvironment in high-grade serous ovarian cancer patients receiving pembrolizumab and lenvatinib monotherapy and combination therapy (NCT05114421)."},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01671-w"},{"key":"cit0026","unstructured":"An open, single-arm clinical study of envafolimab, lenvatinib combined with VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary fallopian tube cancer and primary peritoneal carcinoma (NCT05422183)."},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-529"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.12.013"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30349-8"},{"key":"cit0030","unstructured":"A randomized, double-blind, placebo-controlled, multi-center, phase iii clinical trial evaluating the efficacy and safety of fluzoparib\u00b1apatinib for maintenance treatment in patients with advanced ovarian cancer who have achieved effective response after first-line platinum-containing chemotherapy (NCT04229615)."},{"key":"cit0031","unstructured":"A phase 2 open label, randomised, controlled, multi-centre study to assess the efficacy and safety of fluzoparib combined with apatinib versus fluzoparib monotherapy in the treatment of relapsed ovarian cancer patients (NCT04517357)."},{"key":"cit0032","unstructured":"Camrelizumab combined with apatinib for recurrent platinum-resistant ovarian cancer: a phase 2 single-arm prospective study (NCT04068974)."},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0411"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.005"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-4497"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01801"},{"key":"cit0037","unstructured":"An open label randomized study of navicixizumab plus paclitaxel and navicixizumab monotherapy in comparison to paclitaxel monotherapy in patients with platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer. NCT05043402. \u2022 The only phase III, ongoing trial which will evaluate Navicixumab both as monotherapy and in combination with Paclitaxel, in the platinum-resistant cohort"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.07.002"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.012"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123733"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174438"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611533104"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211039899"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0630-5"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02670-0"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.11.017"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.109"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.07.028"},{"key":"cit0050","unstructured":"A phase 3, multicenter, open-label, randomized study of nemvaleukin alfa in combination with pembrolizumab versus investigator\u2019s choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. (ARTISTRY-7) (NCT05092360). \u2022 The only phase III trial combining Pembrolizumab and Nemvaleukin Alfa"},{"key":"cit0051","unstructured":"Phase 2 study of pembrolizumab, DPX-survivac vaccine and cyclophosphamide in advanced ovarian, primary peritoneal or fallopian tube cancer (2018, 2024) (NCT03029403."},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00334"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02059"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3343"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(21)00680-6"},{"key":"cit0056","unstructured":"Randomized phase III trial on NIraparib-TSR-042 (Dostarlimab) vs physician\u2019s choice chemotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: nItCHE Trial (MITO 33). NCT04679064."},{"key":"cit0057","unstructured":"ENGOT-0V44 The FIRST (First-line ovarian cancer treatment with niraparib plus TSR-042) study: a randomized, double-blind, phase 3 comparison of platinum-based therapy with TSR-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of stage III or IV Nonmucinous epithelial ovarian cancer. NCT03602859."},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6258"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.04.053"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.06.025"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306"},{"key":"cit0062","unstructured":"A randomized phase 2 trial of atezolizumab (MPDL3280A), SGI-110 and CDX-1401 vaccine in recurrent ovarian cancer (NCT03206047)."},{"key":"cit0063","unstructured":"BEACON - A phase II study of bevacizumab, atezolizumab and cobimetinib in patients with recurrent platinum resistant high grade serous ovarian cancer. NCT03363867."},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz253.016"},{"key":"cit0065","unstructured":"A phase III randomised, double-blind, placebo-controlled, multicentre study of durvalumab in combination with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients (DUO-O). NCT03737643."},{"key":"cit0066","unstructured":"Phase II study of ipilimumab monotherapy in recurrent platinum-sensitive ovarian cancer-study results."},{"key":"cit0067","unstructured":"A phase 1-2 study of the combination of olaparib and tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer (NCT02571725)."},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2009.02.001"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909707"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1250"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0703"},{"key":"cit0072","unstructured":"POSITION: a pilot study of induction PARP inhibition in ovarian cancer. NCT02316834."},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361"},{"key":"cit0074","unstructured":"Randomized study of paclitaxel-carboplatin followed by niraparib compared to paclitaxel-carboplatin-bevacizumab followed by Niraparib+Bevacizumab in patients with advanced ovarian cancer, following a front-line complete surgery (NCT05183984)."},{"key":"cit0075","unstructured":"Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer\u2014A randomized controlled chemotherapy-free study. PHASE II AVANOVA2 (2015-2021). NCT02354131."},{"key":"cit0076","unstructured":"A single-arm, prospective, open-label, phase II study to evaluate the efficacy and safety of niraparib combined with bevacizumab in platinum refractory\/resistant recurrent ovarian, fallopian tube or peritoneal cancer. (AVANIRA3) (NCT04556071)."},{"key":"cit0077","unstructured":"Randomised phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer (NCT03117933)."},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.01.015"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-4121"},{"key":"cit0080","unstructured":"A single-arm phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor (NCT04734665)."},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38534-6"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3215"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1340"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0056"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2022.33.e45"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1048"},{"key":"cit0088","unstructured":"ENGOT-0V44 The FIRST (First-line ovarian cancer treatment with niraparib plus TSR-042) study: a randomized, double-blind, phase 3 comparison of platinum-based therapy with TSR-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of Stage III or IV. Nonmucinous Epithelial Ovarian Cancer (NCT03602859."},{"key":"cit0089","unstructured":"A phase Ib study of the oral PARP inhibitor niraparib with the intravenous PI3K inhibitor copanlisib for recurrent endometrial and recurrent ovarian, primary peritoneal, or fallopian tube cancer (2019-2022)."},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102988"},{"key":"cit0091","unstructured":"Phase ll study of a BET inhibitor, ZEN003694, combined with a PARP inhibitor, talazoparib, in patients with recurrent ovarian cancer. NCT05071937."},{"key":"cit0092","unstructured":"BrUOG 390: neoadjuvant treatment with talazoparib for women with newly diagnosed, advanced ovarian cancer associated with a mutation in BRCA1 or BRCA2 (mBRCA) (2021-2027). NCT04598321."},{"key":"cit0093","unstructured":"NOW. Neoadjuvant olaparib window trial in newly diagnosed BRCA-mutant ovarian cancer. (NCT03943173). 2019-2022 [cited 2022 Dec 5]. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03943173"},{"key":"cit0094","unstructured":"Niraparib maintenance in patients with advanced ovarian cancer at neoadjuvant setting - a phase 2, single-arm trial (NEOPRIMA Trial). NCT04284852."},{"key":"cit0095","unstructured":"The NUVOLA TRIAL: neoadjuvant chemotherapy in unresectable oVarian cancer with OLAparib and weekly carboplatin plus paclitaxel: a phase II open-label multicentre study (NCT04261465)."},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2018.1498845"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.3390\/ph14101053"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.016"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.8400"},{"key":"cit0100","unstructured":"A double-blind, placebo-controlled, multicenter clinical trial of intravenous OvaRex\u00ae MAb-B43.13 as post chemotherapy consolidation for epithelial carcinoma of ovarian, tubal or peritoneal origin. (NCT00050375)."},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02456-z"},{"key":"cit0102","unstructured":"A multicenter phase 3, double-blind, placebo-controlled study comparing chemo-immunotherapy (paclitaxel-carboplatin- oregovomab) vs chemotherapy (paclitaxel-carboplatin- placebo) in patients with advanced epithelial ovarian, fallopian tube or peritoneal carcinoma. (NCT04498117), FLORA-5. (2020-2027). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04498117"},{"key":"cit0103","unstructured":"Phase 1b\/2, single arm clinical trial to evaluate the safety and activity of oregovomab and bevacizumab, paclitaxel carboplatin as a combinatorial strategy in subjects with BRCA-wild type platinum sensitive recurrent ovarian cancer. NCT04938583."},{"key":"cit0104","unstructured":"A phase Ib\/IIa clinical trial to evaluate the safety and activity of oregovomab and nivolumab as a combinatorial immunotherapy strategy in patients with recurrent epithelial cancer of ovarian, tubal or peritoneal origin. NCT03100006."},{"key":"cit0105","unstructured":"A phase I\/II clinical trial to evaluate platinum-based chemotherapy, oregovomab and nivolumab in patients with platinum sensitive recurrent epithelial cancer of ovarian, tubal or peritoneal origin. NCT04620954."},{"key":"cit0106","unstructured":"Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive. Recurrent Ovarian Cancer (NCT05335993."},{"key":"cit0107","unstructured":"A phase II study of oregovomab and PLD in PARP inhibitor resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment. NCT05407584."},{"key":"cit0108","unstructured":"Phase 1\/2 study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) administered in combination with cemiplimab or REGN4018 (MUC16xCD3) (2020-2026). NCT04590326."},{"key":"cit0109","unstructured":"A phase 1\/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (2018-2024). NCT03564340."},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01098-8"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32554-X"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0158"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.5942"},{"key":"cit0114","unstructured":"A randomized placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers. ((NCT02151292."},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0219"},{"key":"cit0116","volume-title":"Efficacy of AZD1775 in Parp resistance; A randomized 2-arm, non-comparative phase 2 study of AZD1775 Alone or AZD1775 and olaparib in women with ovarian cancer who have progressed during PARP inhibition","author":"EFFORT"},{"key":"cit0117","unstructured":"https:\/\/ir.zentalis.com\/news-releases\/news-release-details\/zentalis-pharmaceuticals-announces-positive-initial-clinical\/ [cited 2022 Dec 5]"},{"key":"cit0118","unstructured":"A phase 1\/2 dose-escalation and dose-expansion study of ZN-c3 in combination with niraparib in subjects with platinum-resistant ovarian cancer. NCT05198804."},{"key":"cit0119","unstructured":"Phase I study of ZN-c3 and bevacizumab \u00b1 Pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors. NCT05431582."},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02404"},{"key":"cit0121","unstructured":"Phase 2 Study of M6620 (VX-970) in combination with gemcitabine versus gemcitabine alone in subjects with platinum-resistant recurrent ovarian or primary peritoneal fallopian tube cancer. (NCT02595892)."},{"key":"cit0122","unstructured":"An open-label phase 1b study to determine the maximum tolerated and\/or recommended phase 2 dose of the ATR inhibitor BAY 1895344 in combination with PARP inhibitor niraparib, in patients with recurrent advanced solid tumors and ovarian cancer. NCT04267939."},{"key":"cit0123","unstructured":"Combination ATR and PARP Inhibitor (CAPRI) trial with AZD 6738 and olaparib in recurrent ovarian cancer. NCT03462342"},{"key":"cit0124","unstructured":"A study of the safety, tolerability, and pharamcokinetics of MORAb-003, a humanized monoclonal antibody, in subjects with advanced ovarian cancer. NCT00428766."},{"key":"cit0125","unstructured":"A randomized, double-blind, placebo-controlled, phase 3 study to assess the efficacy and safety of weekly MORAb-003 in combination with carboplatin and taxane in subjects with platinum-sensitive ovarian cancer in first relapse. NCT00849667."},{"key":"cit0126","unstructured":"A randomized, double blind, placebo-controlled study of the efficacy and safety oF MORAb-003(Farletuzumab) in combination with paclitaxel therapy in subjects with platinum-resistant or refractory relapsed ovarian cancer. NCT00738699."},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.2596"},{"key":"cit0128","unstructured":"A randomized double-blind phase 3 trial comparing EC145 and pegylated liposomal doxorubicin (PLD\/Doxil\u00ae\/Caelyx\u00ae) in combination versus PLD in participants with platinum-resistant ovarian cancer. NCT01170650."},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0379"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9538"},{"key":"cit0131","unstructured":"A phase 1b\/2 study to evaluate the safety, tolerability and pharmacokinetics of mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin, pembrolizumab, or Bevacizumab + Carboplatin, in adults with folate receptor alpha positive advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (2015-2021). (NCT02606305) FORWARDII.\u2022\u2022 Promising phase Ib\/II trial evaluating different combinations with MIRV, in pre-selected patients"},{"key":"cit0132","unstructured":"SORAYA: a phase 3, single arm study of mirvetuximab soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. (NCT04296890)\u2022 Ongoing phase III trial testing Mirvetuximab Soravstatine in platinum-resistant patients."},{"key":"cit0133","unstructured":"Mirvetuximab soravtansine monotherapy in platinum-sensitive epithelial, peritoneal, and fallopian tube cancers (PICCOLO). NCT05041257. \u2022 Currently ongoing monotherapy, phase II trial evaluating MIRV in platinum-sensitive relapses"},{"key":"cit0134","unstructured":"Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with fra-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second line platinum-based chemotherapy plus bevacizumab. NCT05445778."},{"key":"cit0135","unstructured":"Dose escalation and expansion clinical study to evaluate the safety and efficacy of ELU001 in subjects who have advanced, recurrent or refractory FRa overexpressing tumors. NCT05001282."},{"key":"cit0136","unstructured":"A phase 1 open-label, safety, pharmacokinetic and preliminary efficacy study of STRO-002, an anti-folate receptor alpha antibody drug conjugate, in combination with bevacizumab in patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers). NCT05200364."},{"key":"cit0137","unstructured":"A Phase 1b\/2, first-in-human, dose escalation and expansion study of XMT-1536 in patients with solid tumors likely to express NaPi2b. NCT03319628."},{"key":"cit0138","unstructured":"A phase 3, randomized, double-blind,placebo-controlled, multicenter study of upifitamab rilsodotin (XMT-1536) as post-platinum maintenance therapy for participants with recurrent, platinum-sensitive, ovarian cancer (UP-NEXT). (NCT05329545)."},{"key":"cit0139","unstructured":"An open-label, multicenter, dose escalation and expansion modular, umbrella master study of upifitamab rilsodotin in combination with other agent(s) in participants with high-grade serous ovarian cancer (UPGRADE). NCT04907968"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.001"},{"key":"cit0141","unstructured":"A phase I\/II study evaluating the dosing, safety, efficacy, and biological activity of intraperitoneal gen-1 (il-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer) administered in combination with Neoadjuvant Chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancear (2018-2024). (NCT03393884)."},{"key":"cit0142","unstructured":"Phase 1-2 study of an immunotherapeutic vaccine, DPX-survivac with low dose cyclophosphamide in patients with surgically operable or advanced stage ovarian, fallopian tube or peritoneal cancer. [cited 2022 Jul 28] https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01416038"},{"key":"cit0143","unstructured":"Phase 1b study of extended dosing of an immunotherapeutic vaccine, DPX-survivac with low dose cyclophosphamide in patients with surgically operable or advanced stage ovarian, fallopian tube or peritoneal cancer [cited 2022 Jul 28]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03332576"},{"key":"cit0144","unstructured":"A Phase 1b\/2 Study of an Immunotherapeutic Vaccine, DPX-survivac with low dose cyclophosphamide and epacadostat (INCB024360) in patients with recurrent ovarian cancer [cited 2022 Jul 28]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02785250"},{"key":"cit0145","unstructured":"A phase 2 study of pembrolizumab (MK-3475), DPX-survivac vaccine and low dose of cyclophosphamide combination in patients with advanced ovarian, primary peritoneal or fallopian tube cancer. (NCT03029403)."},{"key":"cit0146","unstructured":"T-cell therapy in combination with nivolumab, relatlimab and ipilimumab for patients with advanced ovarian- fallopian tube- and primary peritoneal cancer [cited 2022 Jul 28]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04611126"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.015"},{"key":"cit0148","unstructured":"A single-arm, open-label study to evaluate safety and efficacy of fully human B7H3 CAR-T in treating patients with recurrent malignant ovarian cancer [cited 2022 Jul 28]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05211557"},{"key":"cit0149","unstructured":"A phase I clinical study to evaluate the safety, tolerability, and efficacy of LCAR-M23, a CAR-T cell therapy targeting MSLN in patients with relapsed and refractory epithelial ovarian cancer [cited 2022 Jul 28]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04562298"},{"key":"cit0150","unstructured":"A phase 1 study to evaluate TAG72-targeting chimeric antigen receptor (CAR) T cells in patients with advanced epithelial ovarian. Cancer [cited 2022 Jul 28]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05225363"},{"key":"cit0151","unstructured":"Phase I\/Ib study evaluating safety and efficacy of PRGN-3005 UltraCAR-T\u00ae (Autologous CAR T Cells) in advanced stage platinum resistant ovarian cancer patients. [cited 2022 Jul 28]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03907527"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184553"},{"key":"cit0153","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2709"},{"key":"cit0154","unstructured":"P53MVA and pembrolizumab in treating patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. NCT03113487."},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0792-9"},{"key":"cit0156","unstructured":"A phase 1, multicentre, open-label,nonrandomised, first-in-human study of OVM-200 as a therapeutic vaccine in patients with locally advanced or metastatic non-small cell lung cancer, ovarian cancer, and prostate cancer. [cited 2022 Jul 28]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05104515"},{"key":"cit0157","unstructured":"Randomized phase II study comparing neo-epitope based vaccine OSE2101 (TEDOPI\u00ae) with or without Anti-PD1 (Pembrolizumab) Versus best supportive care as maintenance treatment in platinum-sensitive recurrent ovarian cancer patient with controlled disease after platinum-based chemotherapy [cited 2022 Jul 28]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04713514"},{"key":"cit0158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01566"},{"key":"cit0159","unstructured":"A phase I trial evaluating a mutanome-directed immunotherapy in patients with high grade serous carcinoma (HGSC) of the ovary, fallopian tube or peritoneum. NCT03839524. \u2022 The first trial studying a personalized vaccine based on a panel of patient-specific mutations that were identified through artificial intelligence"},{"key":"cit0160","doi-asserted-by":"publisher","DOI":"10.1016\/annonc\/annonc276)"},{"key":"cit0161","unstructured":"A randomized phase 3 study assessing the efficacy and safety of olvi-vec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant\/refractory ovarian cancer. NCT05281471)."},{"key":"cit0162","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061607"},{"key":"cit0163","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102298"},{"key":"cit0164","doi-asserted-by":"publisher","DOI":"10.1159\/000448942"},{"key":"cit0165","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14919"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2022.2160313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T12:42:25Z","timestamp":1675168945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2022.2160313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":165,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,2]]}},"alternative-id":["10.1080\/13543784.2022.2160313"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2022.2160313","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}